Flutiform helps Skyepharma to boost first half profit
15th Aug 2013 10:04
Rising sales of asthma treatment Flutiform helped drug developer Skyepharma to boost first half revenue and underlying profit. Skyepharma continued to roll out Flutiform in Europe in the first half including securing approval for the asthma inhaler and launching it in Italy. It is now approved in 2
Read moreSkyePharma on target for full year
15th Oct 2012 07:29
Drug development firm SkyePharma said expectations for 2012 pre-exceptional operating profit remain unchanged and is confident of future trading as it launches its asthma treatment product flutiform across Europe. SkyePharma cautioned that some contract development work has been delayed into 2013 b
Read moreSmall caps round-up: Infrastructure India, SkyePharma, LiDCO Group
23rd Aug 2012 16:00
Infrastructure India, an AIM-listed investment group, pleased its investors with a 50.2 per cent leap in its net asset value (NAV) to 207.3m pounds over the year ended March. The value of the company's investments rose 94.9 per cent to 216.7m pounds, while the NAV per share climbed from 92p to 95p.
Read moreSmall caps round-up: HaiKe Chemical, Mobile Tornado, GETECH...
17th Jul 2012 10:53
HaiKe Chemical Group, a petrochemical, specialty chemical and biochemical business based in China, has purchased a minority stake in Dongying Hi-Tech Ruilin Chemical for a total consideration of RMB121m (c.12m pounds), taking HaiKe's interest in Hi-Tech Ruilin from 65.7 per centto 88.85 per cent. Hi
Read moreSkyepharma rockets on regulatory approval
3rd Jul 2012 14:50
SkyePharma said the European Commission had given it the go-ahead to start marketing its asthma medicine, flutiform, across the continent. The firm said the European Commission's decision was binding and 21 member states were now required to grant national marketing authorisations or approvals cons
Read moreSmall caps round-up: Creon Resources, SkyePharma, Avation
22nd Jun 2012 14:47
The resources investment firm Creon Resources is to raise 12.1m pounds from an open offer, with around 2.4bn shares up for sale at 0.5p per share, a 1.5p discount to the share price at the close yesterday. Jeswant Natarajan, Chief Executive Officer of Creon, commented: 'Today's announcement...is ext
Read moreSmall caps round-up: Games Workshop, Record, ITM ...
20th Apr 2012 09:36
Miniature table-top war games firm Games Workshop said trading in the four months to the beginning of April has been broadly in line with the board's expectations. Specialist currency manager Record has posted assets under management equivalents of $30.9bn (£19.3bn) at March 31st, up from $25.4bn (
Read moreSmall caps round-up: Top Level Domain, Transense, SkyePharma
11th Apr 2012 09:46
Top Level Domain Holdings, which operates generic top-level domains, has revealed that is wholly-owned subsidiary, Minds and Machines, has been appointed by Dot London Domains (DLD), the official promotional organisation for London, to assist with DLD's application for the position of registry opera
Read moreSkyepharma shares up despite falling into the red
22nd Mar 2012 11:43
Shares in SkyePharma rose despite the drug development firm reporting a fall in revenue and a plunge into the red for the year ended December 31st. The firm recorded a pre-tax loss of £1.6m in 2011, down from a profit of £6.3m the year before, on revenues which fell from £58.1m to £55.2m. Peter
Read moreLondon Close: Footsie enjoys pre-Christmas surge
23rd Dec 2011 12:45
Footsie has battled its way above 5500, and there are just a handful of the top-share index's constituents that are not participating in the advance, including banking titans Lloyds, Standard Chartered, HSBC and Royal Bank of Scotland. Hopes that the US recovery is gathering pace and that it might,
Read moreLondon midday: Stocks up on US hopes
23rd Dec 2011 11:43
Shares in London were up as investors began to believe the US recovery is gathering pace, perhaps with the prospect of dragging Europe along with it. The main indicator out of the US will be the number of new home sales, due after the market closes in London but hopes are high the figures will show
Read moreSkyePharma rocked by regulatory delay
23rd Dec 2011 09:38
Drugs developer SkyePharma was sailing close to its 52-week low after it announced another regulatory delay for its asthma treatment, Flutiform. The decentralised procedure (DCP) for the regulatory review of Flutiform has been referred to the European Medicines Agency and its Committee for Medicina
Read moreSkyePharma product application delayed
18th Oct 2011 08:24
Drug developer SkyePharma has announced that a review of the European Marketing Authorisation Application (MAA) for its Flutiform product will take longer than originally anticipated. The delay is due to lack of complete consensus by the concerned members within the timescale laid down by the revie
Read moreSkyepharma sales fall 25%
18th Aug 2011 14:22
Shares in drug developer Skyepharma took a hit on Thursday after the firm announced that revenues fell by 25% in the first half of 2011, due to a tough comparator the year before. Revenues fell to £22.1m in the six months to 30 June, from £29.3m the year before, which benefited from substantial non
Read moreSkyePharma joins forces with Aenova
1st Aug 2011 14:45
Drug developer SkyePharma has entered into an agreement with Aenova to increase utilisation of SkyePharma's manufacturing facility in Saint Quentin-Fallavier, France. The alliance was agreed to provide Aenova with access to a US Food and Drug Administration (FDA)-registered pharmaceutical manufac
Read more